Bio Green Med Solution, Inc. (BGMS)
NASDAQ: BGMS · Real-Time Price · USD
1.660
-0.160 (-8.79%)
At close: Dec 5, 2025, 4:00 PM EST
1.750
+0.090 (5.42%)
After-hours: Dec 5, 2025, 7:58 PM EST
Bio Green Med Solution Revenue
Bio Green Med Solution had revenue of $81.00K in the quarter ending September 30, 2025, with 710.00% growth. This brings the company's revenue in the last twelve months to $81.00K, up 9.46% year-over-year. In the year 2024, Bio Green Med Solution had annual revenue of $43.00K, down -89.76%.
Revenue (ttm)
$81.00K
Revenue Growth
+9.46%
P/S Ratio
21.24
Revenue / Employee
$6,750
Employees
12
Market Cap
8.13M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BGMS News
- 22 days ago - Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB - GlobeNewsWire
- 5 months ago - Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday? - Benzinga
- 5 months ago - CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER - GlobeNewsWire
- 5 months ago - CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT - GlobeNewsWire
- 5 months ago - Cyclacel Pharmaceuticals Announces Stock Split - GlobeNewsWire
- 6 months ago - Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock - GlobeNewsWire